Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

NCT05409378 is registered in ClinicalTrials.gov with HLT Inc. as lead sponsor.

NCT NCT05409378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05409378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation
Lead sponsor
HLT Inc.
Phase
Not applicable
Overall status
Withdrawn
Start date
July 8, 2022
Completion date
January 20, 2023
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aortic regurgitation